ABSTRACT
ObjectiveTo evaluate the methodological quality of systematic review / Meta analysis （SR/MA） of intervention randomized controlled trial （RCT） published in the Sichuan Mental Health. MethodsThe literature databases such as Wanfang Data， China National Knowledge Infrastructure （CNKI）， VIP Database for Chinese Technical Periodical （VIP） and Chinese Biomedical Literature Database （CBM） were searched for the SRs/MAs of intervention RCTs published in the Sichuan Mental Health from the initial issue to the issue published on 31 June 2021. Then the methodological quality of eligible SRs/MAs were assessed using A Measurement Tool to Assess systematic Reviews 2 （AMSTAR 2）. ResultsThe literature search yielded 24 full-text articles， and the mean AMSTAR 2 score of the included SRs/MAs was （5.21±3.63） with a range from 1 to 11. The total AMSTAR 2 score for SRs/MAs showed difference in terms of the publication date prior to or later than the publication of AMSTAR-2 tool （t=-5.499）， number of authors ≤ 2 or ≥ 3 （t=-6.736）， with or without funding support （t=3.329） and author unit nature （F=7.827）， with statistical significance （P<0.01）. All selected studies had deficiencies on explicit statement of a priori design and registrations， list of excluded studies and reasons for exclusion， sources of funding for the research in systematic review， potential conflicts of interest statement， and funding information of the systematic review. ConclusionThe methodological quality of SRs/MAs of intervention RCTs published in the Sichuan Mental Health varies widely， After the release of AMSTAR 2， the methodological quality has improved， but the report still needs to be further standardized to provide high-quality evidence-based evidence.
ABSTRACT
To prolong serum half-life of human kallikrein (hK) and enhance its secretion rate, we modified hK gene and constructed a new form of recombinant hK protein (hK'-Fc). We amplified hK gene and Fc sequence, replaced the signal peptide of hK gene with murine signal peptide, constructed native expression plasmid of pcDNA-hK-Fc and modified expression plasmid of pcDNA-hK'-Fc, then transfected to CHO cells respectively. After the stable cell lines were screened, we compared the secretion rate between native fusion protein and modified fusion protein, purified fusion protein through Protein A+G affinity chromatography column and investigated the bioactivity of fusion protein. The results showed that recombinant vectors encoding fusion protein hK-Fc and hK'-Fc were constructed successfully; CHO cell lines stably secreting fusion protein were obtained, the yield is higher than 11 mg/L; Secretion rate was enhanced by 5-10 times after the signal peptide of fusion protein was modified; Fusion protein has enzymatic activity in vitro. The above results could promote the following researches on serum half-life of the fusion protein and develop a new stroke medicine with better clinical efficacy.